Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.53 |
| ▸ | ACACA | Q13085 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179615 | 0.98 | ACACB (0.50) | ACACBACACAFFAR4FFAR1GPR84 | |
| SCHEMBL12092644 | 0.93 | ACACB (0.47) | ACACBACACAFFAR4FFAR1GPR84 | |
| SCHEMBL6181043 | 0.92 | ACACB (0.42) | ACACBACACAFFAR4FFAR1 | |
| SCHEMBL12092647 | 0.91 | ACACB (0.44) | ACACBACACAFFAR4FFAR1TP53 | |
| SCHEMBL6181280 | 0.86 | ACACB (0.41) | ACACBACACA | |
| SCHEMBL6199247 | 0.83 | ACACB (0.36) | ACACBACACA | |
| SCHEMBL13106127 | 0.82 | ACACB (0.39) | ACACBACACA | |
| SCHEMBL11305436 | 0.81 | ACACB (0.34) | ACACBACACATP53 | |
| SCHEMBL13106118 | 0.80 | ACACB (0.36) | ACACBACACA | |
| SCHEMBL6024339 | 0.77 | GGPS1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9000041-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130289117-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-7812199-B2 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7335799-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289117-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR4 114/4885 |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR4 114/4885 |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR4 114/4885 |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | PNLIP, NR1H3, CYP27A1 | ACACB 220/4885ACACA 202/4885FFAR4 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.